Application Of Contrast—enhanced Ultrasound In Diagnosis And Efficacy Evaluation Of Neoadjuvant Chemotherapy Of Breast Cancer

Objective:Evaluate the diagnosis value of contrast-enhanced ultrasound in breast cancer,and explore the value of the efficacy evaluation of neoadjuvant chemotherapy(NAC) of breast cancer.Method:70 patients with suspected breast malignant tumors from January 2013 to June 2015 underwent contrast-enhanced ultrasound(CEUS),all lesions underwent surgical resection or biopsy in order to definite pathological diagnosis after CEUS.Analyse the morphology enhanced features and time-intensity curves of tumors combining with the pathological results.9cases diagnosed with breast cancer but without surgery accept neoadjuvant chemotherapy treatment,accept inspection of two-dimensional ultrasound and contrast-enhanced ultrasound respectively,observe the lesions’ size and grade of blood flow and internal echo characteristics before and after neoadjuvant chemotherapy treatment,evaluate the efficacy of contrast-enhanced ultrasound of neoadjuvant chemotherapy treatments.Results:The differences of the form,through the blood vessels,the contrast agent distribution around,the peak intensity(PI), time to peak(TTP) between benign and malignant breast tumors had statistical significance(P <0.05).9 cases of patients dignosed breast cancer accept neoadjuvant chemotherapy treatment,there wasn’t significant difference in the changes of lesions’ largest transverse and vertical diameters between onventional ultrasound and contrast-enhanced ultrasound before and after neoadjuvant chemotherapy( P >0.05).The contrast-enhanced ultrasound have an advantage over the conventional ultrasound on displaying intensity of lesions’ perfusion and necrosis area( P <0.05).Conclusions:After ultrasonic imaging,it has the high diagnostic value that heterogeneous distribution,irregular shape,tortuous surrounding vessels,perfusion defect,the mass increased,PI and TTP.Compared with conventional ultrasound,thecontrast-enhanced ultrasound of breast has advantages in the efficacy evaluation of neoadjuvant chemotherapy of breast cancer.